tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

AngioDynamics Inc

ANGO
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
14.480USD
-0.310-2.10%
์ข…๊ฐ€ย 07-31 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
603.56M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

์ž์„ธํ•œ ๋‚ด์šฉ์€ AngioDynamics Inc ํšŒ์‚ฌ

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

AngioDynamics Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ ANGO
ํšŒ์‚ฌ ์ด๋ฆ„AngioDynamics Inc
์ƒ์žฅ์ผMay 27, 2004
CEOClemmer (James C)
์ง์› ์ˆ˜675
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒMay 27
์ฃผ์†Œ14 Plaza Drive
๋„์‹œLATHAM
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ12110
์ „ํ™”15187981215
์›น์‚ฌ์ดํŠธhttps://www.angiodynamics.com/
์ข…๋ชฉ ์ฝ”๋“œ ANGO
์ƒ์žฅ์ผMay 27, 2004
CEOClemmer (James C)

AngioDynamics Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Stephen A. Trowbridge, J.D.
Mr. Stephen A. Trowbridge, J.D.
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
311.25K
-3.88%
Mr. Howard W. Donnelly
Mr. Howard W. Donnelly
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
167.05K
--
Ms. Eileen O'Shea Auen
Ms. Eileen O'Shea Auen
Independent Director
Independent Director
129.72K
--
Ms. Laura Piccinini
Ms. Laura Piccinini
Senior Vice President, General Manager - Endovascular Therapies and International
Senior Vice President, General Manager - Endovascular Therapies and International
94.30K
-8.73%
Mr. Wesley E. Johnson, Jr.
Mr. Wesley E. Johnson, Jr.
Independent Director
Independent Director
--
--
Mr. James C. Clemmer
Mr. James C. Clemmer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Jan Stern Reed
Ms. Jan Stern Reed
Independent Director
Independent Director
--
--
Mr. Warren G. Nighan
Mr. Warren G. Nighan
Senior Vice President - Global Supply Chain, Quality and Regulatory Affairs
Senior Vice President - Global Supply Chain, Quality and Regulatory Affairs
--
--
Mr. Chad T. Campbell
Mr. Chad T. Campbell
Senior Vice President, General Manager - Global Oncology and Vascular Access
Senior Vice President, General Manager - Global Oncology and Vascular Access
--
--
Ms. Karen A. Licitra
Ms. Karen A. Licitra
Independent Director
Independent Director
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Stephen A. Trowbridge, J.D.
Mr. Stephen A. Trowbridge, J.D.
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
311.25K
-3.88%
Mr. Howard W. Donnelly
Mr. Howard W. Donnelly
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
167.05K
--
Ms. Eileen O'Shea Auen
Ms. Eileen O'Shea Auen
Independent Director
Independent Director
129.72K
--
Ms. Laura Piccinini
Ms. Laura Piccinini
Senior Vice President, General Manager - Endovascular Therapies and International
Senior Vice President, General Manager - Endovascular Therapies and International
94.30K
-8.73%
Mr. Wesley E. Johnson, Jr.
Mr. Wesley E. Johnson, Jr.
Independent Director
Independent Director
--
--
Mr. James C. Clemmer
Mr. James C. Clemmer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

AngioDynamics Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
AngioDynamics Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Mr. Stephen A. Trowbridge, J.D.

AngioDynamics Inc(ANGO)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2026Q1 ๊ธฐ์ค€์œผ๋กœ, AngioDynamics Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 321๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 38.82M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 93.94%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q4 ๋Œ€๋น„ -7218201.00 ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ